Aker BioMarine Announces New Research on Lysoveta's EPA and DHA Transfer to the Brain

Aker BioMarine is a leading company in the healthcare and nutrition sectors, developing sustainable marine-derived ingredients. The company leverages the natural nutritional value of krill and algae to address global health challenges. Its products include Superba Krill® Oil and Revervia® algae-derived DHA oil. Aker BioMarine is listed on the Oslo Stock Exchange (OSE). The company has announced new research regarding its novel compound 'Lysoveta' and its ability to facilitate the transfer of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) to the brain. This discovery holds significant implications for brain health and cognitive function, as efficient delivery of these essential fatty acids to the brain is crucial for neurological well-being. The research highlights Aker BioMarine's ongoing commitment to scientific innovation and its mission to provide advanced nutritional solutions derived from sustainable marine sources. This advancement further solidifies the company's position as a pioneer in the field of marine biotechnology and sustainable health solutions.